Top Ten most popular articles on Pharmafile.com this week
As another week comes and goes, waves were sent through the industry as Trump announced his pick as the new Head of the FDA. While we will have to wait to see the effects of his potential choice, there has also been a number of announcements for pharma/university collaborations which may bear fruit in the future. Our new feature on antibiotic resistance has proved popular with readers, as did a story concerning some alarming findings on common painkiller ibuprofen.
Check out a round up of the most read, shared and discussed topics that we featured on our website this week!
Ben Hargreaves looks at the pricing debate occurring within Europe and how it could lead to closer relations between countries within the EU.
Mylan scored a big victory in its plan to launch its biosimilar to Roche’s blockbuster, Herceptin, after Roche and itself agreed a global licensing pact.
Pfizer and Swansea University have announced plans to collaborate on a new Innovation Hub at Swansea University’s new £450 million Bay Campus.
Amgen has filed a lawsuit in a Californian state court against Coherus Biosciences, suggesting that Coherus had stolen trade secrets. The case is in regards to the development of Coherus’ biosimilar to Amgen’s Neulasta.
A study has found that a commonly prescribed treatment for preventing premature births has no benefits and may even increase the risk of gestational diabetes.
There’s a whole lot of explaining to do before many U.S. patients and doctors will feel comfortable with biosimilars in place of their go-to biologics, Clarivate Analytics explains the issues and what can be done.
Dr Scott Gottlieb is Trump’s chosen nominee for the role of commissioner of the FDA. The nomination appeases fears within the pharmaceutical industry and the FDA of an about-turn towards extreme deregulation of the drug approval process.
A study emerging from Denmark has found that the use of over-the-counter pain killer, Ibuprofen, is associated with an increased risk of cardiac arrest. Research found an increase of 31% in cardiac arrest risk through the use of the anti-inflammatory.
The University of Cambridge has announced a new initiative that seeks to build a bridge between industry and academia in the discovery of innovative treatments and diagnostics, known as the Cambridge Academy of Therapeutic Sciences (CATS).
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, 2016 was the year where it really came to the fore. We examine the leading immunotherapies in the market and their development as we move further into 2017.